candesartan has been researched along with Hyperlipidemias in 5 studies
candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.
Hyperlipidemias: Conditions with excess LIPIDS in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "These results suggest that regression of established atherosclerosis lesions in ApoE-deficient mice is feasible using high-dose candesartan, by mechanisms involving (i) a decrease in the lipid-retaining proteoglycan biglycan, and (ii) suppression of ACAT1 expression resulting in increased free cholesterol for lipid release." | 7.78 | Regression of atherosclerosis in apolipoprotein E-deficient mice is feasible using high-dose angiotensin receptor blocker, candesartan. ( Azegami, T; Hayashi, K; Itoh, H; Sasamura, H, 2012) |
| "These results suggest that regression of established atherosclerosis lesions in ApoE-deficient mice is feasible using high-dose candesartan, by mechanisms involving (i) a decrease in the lipid-retaining proteoglycan biglycan, and (ii) suppression of ACAT1 expression resulting in increased free cholesterol for lipid release." | 3.78 | Regression of atherosclerosis in apolipoprotein E-deficient mice is feasible using high-dose angiotensin receptor blocker, candesartan. ( Azegami, T; Hayashi, K; Itoh, H; Sasamura, H, 2012) |
| "Telmisartan is a unique angiotensin II (Ang II) receptor blocker (ARB) with selective peroxisome proliferator-activated receptor-gamma (PPAR gamma)." | 1.35 | Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change. ( Akasaka, T; Goto, M; Ikejima, H; Imanishi, T; Kobayashi, K; Kuroi, A; Mochizuki, S; Muragaki, Y; Shiomi, M; Tsujioka, H; Yoshida, K, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nishida, Y | 1 |
| Takahashi, Y | 1 |
| Nakayama, T | 1 |
| Soma, M | 1 |
| Asai, S | 1 |
| Hayashi, K | 1 |
| Sasamura, H | 1 |
| Azegami, T | 1 |
| Itoh, H | 1 |
| Chen, J | 1 |
| Li, D | 1 |
| Schaefer, RF | 1 |
| Mehta, JL | 1 |
| Messerli, FH | 1 |
| Bangalore, S | 1 |
| Egan, BM | 1 |
| Julius, S | 1 |
| Ikejima, H | 1 |
| Imanishi, T | 1 |
| Tsujioka, H | 1 |
| Kuroi, A | 1 |
| Kobayashi, K | 1 |
| Shiomi, M | 1 |
| Muragaki, Y | 1 |
| Mochizuki, S | 1 |
| Goto, M | 1 |
| Yoshida, K | 1 |
| Akasaka, T | 1 |
5 other studies available for candesartan and Hyperlipidemias
| Article | Year |
|---|---|
Comparative effect of olmesartan and candesartan on lipid metabolism and renal function in patients with hypertension: a retrospective observational study.
Topics: Aged; Angiotensin II Type 2 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Blood Urea Nitrog | 2011 |
Regression of atherosclerosis in apolipoprotein E-deficient mice is feasible using high-dose angiotensin receptor blocker, candesartan.
Topics: Acetyl-CoA C-Acetyltransferase; Angiotensin Receptor Antagonists; Animals; Apolipoproteins E; Athero | 2012 |
Inhibitory effect of candesartan and rosuvastatin on CD40 and MMPs expression in apo-E knockout mice: novel insights into the role of RAS and dyslipidemia in atherogenesis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Arteriosclerosis; Benzimidazole | 2004 |
Does life-long reduction in low-density lipoprotein cholesterol reduce the risk of new-onset hypertension?
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cholesterol, LDL; Humans; Hyperlipidemi | 2006 |
Effects of telmisartan, a unique angiotensin receptor blocker with selective peroxisome proliferator-activated receptor-gamma-modulating activity, on nitric oxide bioavailability and atherosclerotic change.
Topics: Angiotensin II Type 1 Receptor Blockers; Anilides; Animals; Aorta, Abdominal; Aorta, Thoracic; Ather | 2008 |